Short-Term Efficacy and Safety of Basal-Bolus Insulin Regimens in Renal Transplant Recipients With Pre-existing Type 2 Diabetes Mellitus in Early Post-transplant Outpatient Settings
Introduction Glycemic control is important for allograft and patient survival in renal transplant recipients. We evaluated short-term treatment outcomes of basal-bolus insulin regimens during outpatient diabetes management in renal transplant recipients with pre-existing diabetes. Materials and methods In this 24-week retrospective observational study, 112 adults with pre-existing type 2 diabetes mellitus (T2DM) who underwent renal transplantation were evaluated for changes in HbA1c, fasting plasma glucose (FPG), postprandial plasma glucose (PPG), serum creatinine, estimated glomerular filtration rate (eGFR), body weight, and hypoglycemic episodes during 24 weeks of outpatient management with basal-bolus insulin regimens. Results Basal-bolus insulin therapy was associated with significant reductions in mean HbA1c (8.9% to 7.2%; p < 0.001), FPG (237.9 to 122.3 mg/dL; p < 0.001), and PPG (342.2 to 173.0 mg/dL; p < 0.001). Overall, 45.5% of patients achieved HbA1c ≤7%, while 46.4% achieved HbA1c >7% and <8%. Body weight increased modestly (mean weight gain of 1.24 kg), with numerically greater weight gain in the glargine group, although the difference was not statistically significant in the primary analysis (p = 0.061). No statistically significant differences in glycemic or renal outcomes were observed between the degludec and glargine groups or between the regular human insulin and insulin aspart groups. Nocturnal hypoglycemia occurred in four of 60 (6.7%) patients receiving degludec and seven of 52 (13.5%) patients receiving glargine; however, the difference was not statistically significant (p = 0.341). Conclusions Glycemic control improved over 24 weeks among renal transplant recipients with pre-existing T2DM receiving basal-bolus insulin therapy, without deterioration in measured renal function parameters. No statistically significant differences in glycemic outcomes or the proportions of patients experiencing nocturnal hypoglycemia were observed between the degludec and glargine groups.
Authors
- Debmalya Sanyal (ORCID: https://orcid.org/0000-0002-8186-3697)
- Sourav Das Choudhury
Publication Details
- Journal
- Cureus
- Published
- 2026-11-18
- DOI
- https://doi.org/10.7759/cureus.119913
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00